Article
Microbiology
Jong-Hyuk Baek, Sang-Ho Cha, Sun-Hee Cho, Myung-Shin Lee, Changhoon Park
Summary: The study determined the optimal vaccine dosage of PCV2d capsid protein, showing that dosages greater than 10 μg significantly reduced PCV2d viremia and lymphoid lesions, and produced higher levels of neutralizing antibodies for increased protective efficacy. Conversely, pigs vaccinated with 2 μg had insufficient neutralizing antibodies, resulting in similar viral replication levels to unvaccinated challenged pigs.
Article
Immunology
Zhimin Zhao, Yao Deng, Peihua Niu, Jingdong Song, Wen Wang, Yongping Du, Baoying Huang, Wenling Wang, Leiliang Zhang, Ping Zhao, Wenjie Tan
Summary: The study found that co-immunization with DNA and VLP induced the highest levels of antigen-specific IgG and neutralizing activity, while DNA vaccination alone induced the strongest cellular immunity. All vaccine groups were able to protect mice from lethal CHIKV challenge, but mice co-immunized with DNA and VLP exhibited the best protective effects, with the mildest histopathological changes and lowest scores.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Virology
Shuang Liu, Ping Wang, Xiaolu Shi, Tingsong Weng, Jiayi Zhong, Xiaomin Zhang, Jing Qu, Long Chen, Qing Xu, Xiang Meng, Husheng Xiong, Dawei Wu, Dajun Fang, Bo Peng, Dingmei Zhang
Summary: This study investigates the transfer of maternal antibodies after SARS-CoV-2 vaccination during early pregnancy and its protective effects on infants. The results show that a majority of vaccinated pregnant women can transfer antibodies to newborns, but the levels of neonatal antibodies are relatively low and provide limited protection to infants. Further analysis reveals that women who received three doses of the vaccine or had a longer interval between infection and delivery have higher antibody transfer rates and neonatal antibody titers.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Bertrand Bellier, Alicia Saura, Lucas A. Lujan, Cecilia R. Molina, Hugo D. Lujan, David Klatzmann
Summary: Developed a thermostable orally administered vaccine that induces a robust mucosal immune response and provides complete protection against SARS-CoV-2 in mice and hamsters.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Dmitri Kazmin, Elizabeth A. A. Clutterbuck, Giorgio Napolitani, Amanda L. L. Wilkins, Andrea Tarlton, Amber J. J. Thompson, Emmanuele Montomoli, Guilia Lapini, Smiti Bihari, Rachel White, Claire Jones, Matthew D. D. Snape, Ushma Galal, Ly-Mee Yu, Rino Rappuoli, Giuseppe Del Giudice, Andrew J. J. Pollard, Bali Pulendran
Summary: This study conducted a systematic analysis of immune responses to the trivalent inactivated influenza vaccine adjuvanted with MF-59 in pediatric and adult populations. The results showed that primary vaccination induced a persistent innate immune response, while booster vaccination enhanced the memory-like innate response. Additionally, the study identified transcriptional signatures associated with reactogenicity and immunogenicity in infants.
Article
Immunology
Keon-Woong Yoon, Ki-Back Chu, Hae-Ji Kang, Min-Ju Kim, Gi-Deok Eom, Jie Mao, Su-Hwa Lee, Md Atique Ahmed, Fu-Shi Quan
Summary: This study found that oral immunization with Toxoplasma gondii vaccines induced a similarly effective immune response as intranasal or intramuscular immunizations, providing a protective effect against lethal infections in mice.
Article
Virology
Zach Menne, Vasilis C. Pliasas, Richard W. Compans, Sheniqua Glover, Constantinos S. Kyriakis, Ioanna Skountzou
Summary: The study demonstrates that vaccination with neuraminidase VLPs is protective against influenza challenge, and bivalent vaccination can effectively protect against lethal challenge from different subtypes of influenza viruses.
Article
Medical Laboratory Technology
Silvia Meschi, Giulia Matusali, Francesca Colavita, Daniele Lapa, Licia Bordi, Vincenzo Puro, Bruno D. Leoni, Claudio Galli, Maria Rosaria Capobianchi, Concetta Castilletti
Summary: The study found a significant correlation between antibody response and virus neutralization titer, with 2,000 BAU/mL serving as a predictive threshold for strong neutralization response in vaccinated individuals.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2021)
Article
Microbiology
Mengkai Cai, Ping Gan, Xiaokun Hu, Zhanzhuo Mai, Chihai Ji, Heyou Yi, Meidi Li, Shaofang Li, Yikuan Ji, Junmei Huang, Guihong Zhang, Lang Gong
Summary: This study developed a vaccine using virus-like particles (VLPs) that can protect against both EA H1N1 and human-like H3N2 infections. The vaccine induced strong immune responses in mice and provided partial or complete protection against different subtypes of the virus.
VETERINARY MICROBIOLOGY
(2022)
Article
Virology
Michele Bergmann, Monika Freisl, Yury Zablotski, Md Anik Ashfaq Khan, Stephanie Speck, Uwe Truyen, Katrin Hartmann
Summary: This study found that the majority of healthy adult dogs, who had not been vaccinated against CDV, already had antibodies before vaccination, but did not show an antibody response after vaccination. Young age was significantly associated with a lack of pre-vaccination antibodies.
Article
Oncology
Lara Victoria Donhauser, Julia Veloso de Oliveira, Cordula Schick, Wenzel Manlik, Sabrina Styblova, Sarah Lutzenberger, Michael Aigner, Patrick Philipp, Sebastian Robert, Beate Gandorfer, Dirk Hempel, Louisa Hempel, Dietmar Zehn
Summary: The study analyzed the response to BioNTech/Pfizer's anti-SARS-CoV-2 mRNA vaccine in 237 oncology outpatients and found that patients should wait at least 6 months to 12 months after systemic therapy before receiving mRNA vaccination.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Mona O. Mohsen, Martin F. Bachmann
Summary: Virus-like particles (VLPs) have become versatile tools in various fields, including biology, medicine, and engineering. They can be used to study viral structures, develop vaccines, deliver pharmaceuticals, and treat a range of diseases.
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Min-Ju Kim, Ki-Back Chu, Hae-Ji Kang, Keon-Woong Yoon, Gi-Deok Eom, Jie Mao, Su-Hwa Lee, Jeeva Subbiah, Sang-Moo Kang, Eun-Kyung Moon, Fu-Shi Quan
Summary: Heterologous prime-boost immunization using rBV, VLP, and rVV vaccines was effective against P. berghei infection, providing evidence for its potential implementation.
Article
Immunology
Julio Carrera, Turgut E. Aktepe, Linda Earnest, Dale Christiansen, Adam K. Wheatley, Hyon-Xhi Tan, Amy W. Chung, Simon Collett, Kirsty McPherson, Joseph Torresi, Jason M. Mackenzie, Cameron P. Simmons
Summary: In this study, a ZIKV virus-like particle (VLP) based vaccine candidate was developed and its immunogenicity was evaluated in mice. The unadjuvanted ZIKV-VLPs or inactivated ZIKV generated a lasting immune response, but did not neutralize ZIKV infection in vitro. However, when co-administered with Aluminium hydroxide, the ZIKV VLPs not only produced neutralizing antibodies, but also generated more antigen-specific memory B cells, making it a suitable single dose vaccine candidate for outbreak settings.
Article
Biochemistry & Molecular Biology
Atefeh Arab, Amin Reza Nikpoor, Peyman Asadi, Reza Iraei, Rezvan Yazdian-Robati, Afsana Sheikh, Prashant Kesharwani
Summary: Virus-like nanoparticles (VLPs) are structures resembling viruses but without viral genomes, commonly used in vaccine designs. They can induce both cellular and humoral immunity due to their unique properties and repetitive structure. The size of most VLPs allows them to easily enter lymphatic vessels and stimulate the immune system without the need for adjuvants. Research has focused on using VLP-based technology to design vaccines that are more effective in preventing and treating cancer.
PROCESS BIOCHEMISTRY
(2022)